<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10289750</article-id><article-id pub-id-type="pmcid-ver">PMC10289750.1</article-id><article-id pub-id-type="pmcaid">10289750</article-id><article-id pub-id-type="pmcaiid">10289750</article-id><article-id pub-id-type="pmid">37352067</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000034109</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>5300</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true" content-type="https://orcid.org/0000-0002-2594-1048">https://orcid.org/0000-0002-2594-1048</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="JH">Jong Hun</given-names></name><degrees>MD, PhD</degrees><email>rehappydoc@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="D">Dougho</given-names></name><degrees>MD, PhD</degrees><email>parkdougho@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lim</surname><given-names initials="HS">Hyun Sun</given-names></name><degrees>PhD</degrees><email>hsunlim@nhimc.or.kr</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kang</surname><given-names initials="MJ">Min Jin</given-names></name><degrees>BS</degrees><email>kangmj@nhimc.or.kr</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JH">Jun Hong</given-names></name><degrees>MD</degrees><email>jhlee@nhimc.or.kr</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yoon</surname><given-names initials="SY">Seo Yeon</given-names></name><degrees>MD, PhD</degrees><email>seoyeon0521@gmail.com</email><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true" content-type="https://orcid.org/0000-0002-5310-4802">https://orcid.org/0000-0002-5310-4802</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="HS">Hyoung Seop</given-names></name><degrees>MD, PhD</degrees><xref rid="aff5" ref-type="aff">e</xref><xref rid="c1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><aff id="aff1"><label>a</label> Department of Neurology, National Health Insurance Service Ilsan Hospital, Goyang, South Korea</aff><aff id="aff2"><label>b</label> Department of Rehabilitation Medicine, Pohang Stroke and Spine Hospital, Pohang, South Korea</aff><aff id="aff3"><label>c</label> Research and Analysis Team, National Health Insurance Service Ilsan Hospital, Goyang, South Korea</aff><aff id="aff4"><label>d</label> Department of Physical Medicine &amp; Rehabilitation, Korea University Guro Hospital, Seoul, Republic of Korea</aff><aff id="aff5"><label>e</label> Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.</aff></contrib-group><author-notes><corresp id="c1">* Correspondence: Hyoung Seop Kim, Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, 100 Ilsan-ro, Goyang 10444, South Korea (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="rehappydoc@gmail.com">rehappydoc@gmail.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>23</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2023</year></pub-date><volume>102</volume><issue>25</issue><issue-id pub-id-type="pmc-issue-id">439036</issue-id><elocation-id>e34109</elocation-id><history><date date-type="received"><day>29</day><month>10</month><year>2022</year></date><date date-type="rev-recd"><day>4</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>5</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>24</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-26 17:25:20.960"><day>26</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC)</ext-link>, where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-102-e34109.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-102-e34109.pdf"/><abstract><p>To evaluate the effects of aspirin in the primary prevention, we evaluated disability grades and mortality after ischemic/hemorrhagic stroke and myocardial infarction (MI). A retrospective nation-wide propensity score-matched cohort study was performed using the Korean National Health Information Database. From 3,060,639 subjects who were older than 55 and performed national health examinations in 2004 and 2005, we selected the aspirin group (N = 8770) was composed of patients who had received aspirin prior to cardiovascular events. Cox proportional hazards model was used to compare the acquisition times for neurologic disability grades and survival times between the aspirin and control groups. Only in hemorrhagic stroke, the severe neurologic disability risk was higher in the aspirin group (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.02&#8211;1.42). The aspirin group was associated with higher 90-day (HR, 1.33; 95% CI, 1.23&#8211;1.44) and long-term mortality risk (HR, 1.06; 95% CI, 1.03&#8211;1.10) after pooling 3 events. The old age was a strong risk factor for 90-day mortality in hemorrhagic stroke (50s: reference; 60s: HR 2.21, 95% CI 1.50&#8211;3.25; 70s: HR 3.63, 95% CI 2.48&#8211;5.30; 80s: HR 6.69, 95% CI 4.54&#8211;9.65; &gt;90s: HR 11.28, 95% CI 6.46&#8211;19.70). Pre-aspirin use in cardiovascular events has detrimental effects on severe neurological disability in hemorrhagic stroke and short-/long-term mortality in 3 cardiovascular events. The use of aspirin for the primary prevention especially in the elderly should be very cautious because the old age is a strong risk factor for 90-day mortality after hemorrhagic stroke.</p></abstract><kwd-group><kwd>aspirin</kwd><kwd>cardiovascular disease</kwd><kwd>disability</kwd><kwd>mortality</kwd><kwd>primary prevention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Antiplatelet drugs are widely used for the secondary prevention of stroke because antiplatelet therapy has been proven to have larger benefits than risk.<sup>[<xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R4" ref-type="bibr">4</xref>]</sup> However, the effects of antiplatelet in primary prevention for cardiovascular events and mortality after stroke have been controversial.<sup>[<xref rid="R5" ref-type="bibr">5</xref>&#8211;<xref rid="R7" ref-type="bibr">7</xref>]</sup> Results have been varied according to the subjects who were enrolled in the studies, and the recommendation of aspirin was different considering the risk factors for cerebrovascular disease and demographic factors such as sex and age.<sup>[<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]</sup></p><p>The effects of prior antiplatelet therapy on functional outcomes and other complications have been studied.<sup>[<xref rid="R10" ref-type="bibr">10</xref>&#8211;<xref rid="R13" ref-type="bibr">13</xref>]</sup> Some previous researches concluded that antiplatelet therapy was not associated with mortality after ischemic stroke regardless of the timing of morality and all-cause mortality.<sup>[<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup> A recent study about the association with stroke severity and prior antithrombotic therapy showed that antiplatelet therapy could decrease initial stroke severity<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> and infarction volume.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup></p><p>The primary prevention of aspirin can be expected to be effective in the high-risk groups because the secondary prevention of aspirin has proven its effectiveness.<sup>[<xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R4" ref-type="bibr">4</xref>]</sup> However, in the recent primary prevention studies targeting the high-risk groups, the incidence of cardiovascular events was much lower than expected.<sup>[<xref rid="R15" ref-type="bibr">15</xref>&#8211;<xref rid="R19" ref-type="bibr">19</xref>]</sup> On the other hand, if national-wide retrospective data is used, large-scale data can be used, but it may be vulnerable to immortal or selection biases.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> In this study, to avoid these biases, we pooled patients with first-ever hemorrhagic/ischemic stroke and myocardial infarction (MI) with nation-wide data and reconsidered the use of aspirin for the primary prevention by studying how previous aspirin use affects the prognosis.</p></sec><sec sec-type="methods"><title>2. Methods</title><sec><title>2.1. Database and participants</title><p>This study used the Korean National Health Insurance Service (NHIS) cohort. All Korean citizens are obligated to join the National Health Security System, which comprises the NHI and Medical Aid and is overseen by the Ministry of Health and Welfare. The data include a unique anonymous number for each patient and summarize age, gender, type of insurance, a list of diagnoses according to the International Classification of Diseases-10, medical costs claimed, prescribed drugs, biannual health examination data, and death records.</p><p>A retrospective nation-wide propensity score-matched cohort study was performed using NHIS data for those above 55 years who had received health examinations in 2004 and 2005 (Fig. <xref rid="F1" ref-type="fig">1</xref>). From this pool of 3,060,639 subjects, 303,595 subjects were admitted to hospitals with a diagnosis of stroke (ischemic and hemorrhagic) and MI from 2004 to 2007. We excluded 21,964 subjects who visited hospitals with stroke and MI in 2003. We also excluded 15,601 subjects with hemorrhagic and thrombotic conditions and subjects who took other antiplatelet agents and anticoagulants before the events. The criteria for the aspirin group were as follows: patients who showed a rate of prescription compliance above 70% during 1 year before stroke and MI, and took aspirin at least on the days of stroke and MI by calculating the number of aspirin pills from the last prescription day. Finally, 266,031 subjects were selected. Among them, the aspirin group included 8770 subjects. We selected a comparison group from the control group using a 1:2 propensity score matching age, sex, hypertension, diabetes, dyslipidemia, and household income. We could track each patient 17 years from 2004 to 2021. This study was based on the data from NHIS; therefore, informed consent was not obtained individually. The study was approved by the Institutional Review Board of Ilsan hospital (NHIMC 2022-06-013).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Flow chart of subject inclusion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-102-e34109-g001.jpg"/></fig></sec><sec><title>2.2. Independent variables</title><p>Demographic characteristics including age, sex, hypertension, diabetes, dyslipidemia, and household income were analyzed. Among hospital-admitted subjects, ischemic (I63) and hemorrhagic strokes (I60, I61.0&#8211;I61.3) and MI (I21&#8211;I23) were defined according to International Classification of Diseases-10 codes. Regarding stroke, we checked if the subjects underwent computer tomography or magnetic resonance images within 7 days before and after stroke. Details for variables were obtained from health examination data and medical records; total cholesterol level (mmol/L), systolic and diastolic blood pressure (mm Hg), and fasting glucose level (mmol/L) were measured after overnight fasting at regular medical checkup programs. Hypertension, diabetes mellitus, and dyslipidemia were identified by health examination data (systolic blood pressure &#8805; 140&#8201;mm Hg or diastolic blood pressure &#8805; 90&#8201;mm Hg for hypertension, fasting glucose &#8805; 7.0 mmol/L for diabetes mellitus, and total cholesterol &gt; 6.2 mmol/L for dyslipidemia) or specific medications for those diseases. We categorized 3 individual economic status levels according to annual income. The grades of neurologic disabilities are examined by medical specialists of neurology, neurosurgery, or rehabilitation medicine after 6 months of events. The National Pension Service reviews grades for disabilities. Because the acquisition time of disability grade was expressed as year unit, we extrapolated the time to the end of the year. The minimum neurologic disability grade is equivalent to a modified Barthel index of 96, and a severe neurologic disability grade is determined from an modified Barthel index of 53.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup></p></sec><sec><title>2.3. Statistical analysis</title><p>Baseline categorical variables were expressed as numbers and percentages and compared using the chi-square test. We estimated favorable or unfavorable outcomes for disability and mortality after stroke and MI by applying a Cox proportional hazards regression model. The statistical packages SAS System for Windows, version 9.2 (SAS Institute, Cary, NC) was used to perform the analyses in this study. A significance level of 0.05 was selected. The graphs for the hazards ratio were drawn using the &#8220;moonBook&#8221; packages of R (version 4.0.3).</p></sec></sec><sec sec-type="results"><title>3. Results</title><p>Table <xref rid="T1" ref-type="table">1</xref> presents the characteristics of the study population for the 2 cohorts: the aspirin group and the control group. We examined 8770 patients who received aspirin therapy and 17,540 matched comparison subjects. There was no significant difference in age, sex, the prevalence of hypertension, diabetes, dyslipidemia, or income because these variables were used for propensity score matching.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Control (N = 17,540)</th><th align="center" rowspan="1" colspan="1">Aspirin (N = 8770)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Age</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;55&#8211;59</td><td align="center" rowspan="1" colspan="1">2252 (12.8%)</td><td align="center" rowspan="1" colspan="1">1129 (12.9%)</td><td align="center" rowspan="5" colspan="1">.946</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;60&#8211;69</td><td align="center" rowspan="1" colspan="1">5980 (34.1%)</td><td align="center" rowspan="1" colspan="1">2982 (34.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;70&#8211;79</td><td align="center" rowspan="1" colspan="1">6597 (37.6%)</td><td align="center" rowspan="1" colspan="1">3297 (37.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;80&#8211;89</td><td align="center" rowspan="1" colspan="1">2531 (14.4%)</td><td align="center" rowspan="1" colspan="1">1262 (14.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;90</td><td align="center" rowspan="1" colspan="1">180 (1.0%)</td><td align="center" rowspan="1" colspan="1">100 (1.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Women</td><td align="center" rowspan="1" colspan="1">9226 (52.6%)</td><td align="center" rowspan="1" colspan="1">4613 (52.6%)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">7272 (41.5%)</td><td align="center" rowspan="1" colspan="1">3634 (41.4%)</td><td align="center" rowspan="1" colspan="1">.982</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">17,302 (98.6%)</td><td align="center" rowspan="1" colspan="1">8652 (98.7%)</td><td align="center" rowspan="1" colspan="1">.985</td></tr><tr><td align="left" rowspan="1" colspan="1">hld_rf</td><td align="center" rowspan="1" colspan="1">10,258 (58.5%)</td><td align="center" rowspan="1" colspan="1">5123 (58.4%)</td><td align="center" rowspan="1" colspan="1">.926</td></tr><tr><td align="left" colspan="4" rowspan="1">Income</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Low</td><td align="center" rowspan="1" colspan="1">5372 (30.6%)</td><td align="center" rowspan="1" colspan="1">2685 (30.6%)</td><td align="center" rowspan="3" colspan="1">.997</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Middle</td><td align="center" rowspan="1" colspan="1">5024 (28.6%)</td><td align="center" rowspan="1" colspan="1">2509 (28.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;High</td><td align="center" rowspan="1" colspan="1">7144 (40.7%)</td><td align="center" rowspan="1" colspan="1">3576 (40.8%)</td></tr><tr><td align="left" colspan="4" rowspan="1">Disease</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Ischemic stroke</td><td align="center" rowspan="1" colspan="1">9772 (55.7%)</td><td align="center" rowspan="1" colspan="1">4886 (55.7%)</td><td align="center" rowspan="3" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">5376 (30.6%)</td><td align="center" rowspan="1" colspan="1">2688 (30.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;All strokes</td><td align="center" rowspan="1" colspan="1">2392 (13.6%)</td><td align="center" rowspan="1" colspan="1">1196 (13.6%)</td></tr></tbody></table></table-wrap><p>After 2 years of ischemic stroke, the neurologic disability grades did not differ between the 2 groups when all neurologic disability grades (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.89&#8211;1.06; <italic toggle="yes">P</italic> = .47) and severe neurologic disability (HR, 0.99; 95% CI, 0.88&#8211;1.11; <italic toggle="yes">P</italic> = .83) were included (Tables <xref rid="T2" ref-type="table">2</xref> and <xref rid="T3" ref-type="table">3</xref>; Figure S1, Supplemental Digital Content, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/MD/J176" ext-link-type="uri">http://links.lww.com/MD/J176</ext-link>). In hemorrhagic stroke, there was no difference when all neurologic disabilities were included (HR, 1.12; 95% CI, 0.97&#8211;1.30; <italic toggle="yes">P</italic> = .12). However, when only severe neurologic disabilities were assessed, more disabilities were registered in the aspirin group (HR, 1.21; 95% CI, 1.02&#8211;1.42; <italic toggle="yes">P</italic> = .02). When cerebral infarction and cerebral hemorrhage were pooled, the registration of neurologic disability did not show any difference when including all disabilities (HR, 1.0; 95% CI, 0.92&#8211;1.07; <italic toggle="yes">P</italic> = .92) and severe neurologic disabilities (HR, 1.04; 95% CI, 0.95&#8211;1.15; <italic toggle="yes">P</italic> = .40).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Cox proportional hazards models for neurologic disability grades 2 years after events.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">&#946;</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" rowspan="1" colspan="1">&#8211;0.032</td><td align="center" rowspan="1" colspan="1">0.045</td><td align="center" rowspan="1" colspan="1">0.97 (0.89&#8211;1.06)</td><td align="center" rowspan="1" colspan="1">.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">0.075</td><td align="center" rowspan="1" colspan="1">1.12 (0.97&#8211;1.30)</td><td align="center" rowspan="1" colspan="1">.12</td></tr><tr><td align="left" rowspan="1" colspan="1">All strokes</td><td align="center" rowspan="1" colspan="1">&#8211;0.0037</td><td align="center" rowspan="1" colspan="1">0.039</td><td align="center" rowspan="1" colspan="1">1.0 (0.92&#8211;1.07)</td><td align="center" rowspan="1" colspan="1">.93</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI = confidence, HR = hazard ratio, SE = standard error interval.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Cox proportional hazards models for severe neurologic disability grades 2 years after events.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">&#946;</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" rowspan="1" colspan="1">&#8211;0.012</td><td align="center" rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">0.99 (0.88&#8211;1.109)</td><td align="center" rowspan="1" colspan="1">.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">0.086</td><td align="center" rowspan="1" colspan="1">1.23 (1.04&#8211;1.456)</td><td align="center" rowspan="1" colspan="1">.016</td></tr><tr><td align="left" rowspan="1" colspan="1">All strokes</td><td align="center" rowspan="1" colspan="1">0.041</td><td align="center" rowspan="1" colspan="1">0.049</td><td align="center" rowspan="1" colspan="1">1.04 (0.95&#8211;1.15)</td><td align="center" rowspan="1" colspan="1">.40</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI = confidence interval, HR = hazard ratio, SE = standard error.</p></fn></table-wrap-foot></table-wrap><p>For 90-day mortality which is affected directly by recently preceding cardiovascular events, ischemic stroke (HR, 1.40; 95% CI, 1.22&#8211;1.61; <italic toggle="yes">P</italic> &lt; .001), hemorrhagic stroke (HR, 1.52; 95% CI, 1.30&#8211;1.78; <italic toggle="yes">P</italic> &lt; .001), and myocardial infarction (HR, 1.20; 95% CI, 1.06&#8211;1.35; <italic toggle="yes">P</italic> = .003) had higher risks of death in the aspirin group (Table <xref rid="T4" ref-type="table">4</xref>). The risk of 90-day mortality after hemorrhagic stroke was highly affected by age: if compared with the risks of the age of fewer than 60 years, 60s (HR 2.21, 95% CI 1.50&#8211;3.25; <italic toggle="yes">P</italic> &lt; .001), 70s (HR 3.63, 95% CI 2.48&#8211;5.30; <italic toggle="yes">P</italic> &lt; .001), those in their 80s (HR 6.69, 95% CI 4.54&#8211;9.65; <italic toggle="yes">P</italic> &lt; .001), and those in their 90s or older (11.28, 95% CI 6.46&#8211;19.70; <italic toggle="yes">P</italic> &lt; .001) significantly increased the risk of the 90-day death (Fig. <xref rid="F2" ref-type="fig">2</xref>). The old age was also a strong risk factor for 90-day mortality after ischemic stroke and MI (data not shown). The 90-day mortality risk was higher in women than in men (HR 1.18, 95% CI 1.09&#8211;1.27; <italic toggle="yes">P</italic> &lt; .001). For long-term mortality, only hemorrhagic stroke (HR, 1.17; 95% CI, 1.08&#8211;1.27; <italic toggle="yes">P</italic> = .0002) had a higher risk of death in the aspirin group (Table <xref rid="T5" ref-type="table">5</xref>). If all 3 cardiovascular events are pooled, the 90-day (HR, 1.33; 95% CI, 1.23&#8211;1.44; <italic toggle="yes">P</italic> &lt; .001) and long-term (HR, 1.06; 95% CI, 1.03&#8211;1.10; <italic toggle="yes">P</italic> =&lt; .001) mortalities are higher in the aspirin group (Tables <xref rid="T4" ref-type="table">4</xref> and <xref rid="T5" ref-type="table">5</xref>; Figure S2, Supplemental Digital Content, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/MD/J177" ext-link-type="uri">http://links.lww.com/MD/J177</ext-link>).</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Cox proportional hazards models for 90-day mortality.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">&#946;</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" rowspan="1" colspan="1">0.34</td><td align="center" rowspan="1" colspan="1">0.070</td><td align="center" rowspan="1" colspan="1">1.40 (1.22&#8211;1.61)</td><td align="center" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1">0.060</td><td align="center" rowspan="1" colspan="1">1.12 (1.06&#8211;1.35)</td><td align="center" rowspan="1" colspan="1">.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">0.079</td><td align="center" rowspan="1" colspan="1">1.52 (1.30&#8211;1.78)</td><td align="center" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="center" rowspan="1" colspan="1">0.29</td><td align="center" rowspan="1" colspan="1">0.040</td><td align="center" rowspan="1" colspan="1">1.33 (1.23&#8211;1.44)</td><td align="center" rowspan="1" colspan="1">&lt;.001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI = confidence interval, HR = hazard ratio, SE = standard error.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>Cox proportional hazards models for long-term mortality.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">&#946;</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" rowspan="1" colspan="1">0.042</td><td align="center" rowspan="1" colspan="1">0.022</td><td align="center" rowspan="1" colspan="1">1.04 (1&#8211;1.09)</td><td align="center" rowspan="1" colspan="1">.0501</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">0.056</td><td align="center" rowspan="1" colspan="1">0.030</td><td align="center" rowspan="1" colspan="1">1.06 (0.998&#8211;1.12)</td><td align="center" rowspan="1" colspan="1">.057</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">0.158</td><td align="center" rowspan="1" colspan="1">0.043</td><td align="center" rowspan="1" colspan="1">1.17 (1.08&#8211;1.273)</td><td align="center" rowspan="1" colspan="1">.0002</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="center" rowspan="1" colspan="1">0.062</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">1.06 (1.03&#8211;1.10)</td><td align="center" rowspan="1" colspan="1">.0001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI = confidence interval, HR = hazard ratio, SE = standard error.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>The hazard ratios of 90-day mortality after hemorrhagic stroke according to age groups and genders in the aspirin group. We adjusted the models for income levels and prevalences of hypertension, dyslipidemia, and hypertension.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-102-e34109-g002.jpg"/></fig></sec><sec sec-type="discussion"><title>4. Discussion</title><p>We examined 8770 patients with prior aspirin therapy and matched comparison subjects from a nation-wide cohort database of 3,080,639 Korean populations who were older than 55. By pooling hemorrhagic/ischemic stroke and MI, we could estimate the overall effects of aspirin at the population level. Our results demonstrate that prior aspirin therapy significantly increased severe neurologic disability in hemorrhagic stroke and 90-day and long-term mortality rates in all 3 cardiovascular events. For the 90-day mortality of hemorrhagic stroke, which can be regarded as a direct consequence of hemorrhagic stroke, the old age is the most critical factor.</p><p>In this retrospective large-scale cohort study using NHIS data, aspirin therapy had no benefit in the prognosis of cardiovascular events. Antiplatelet drugs showed a beneficial effect on secondary prevention for cardiovascular events but had complications, including bleeding risk.<sup>[<xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R4" ref-type="bibr">4</xref>]</sup> Thus, antiplatelets should be prescribed considering the risk and benefit for each individual. A meta-analysis by Antithrombotic Trialists&#8217; Collaboration presented that the primary prevention effect of aspirin on ischemic stroke was insignificant.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Another meta-analysis of randomized trials in 2019 showed that aspirin did not significantly reduce ischemic stroke occurrence in patients without previous cardiovascular event, and aspirin also did not show any beneficial effect on the primary prevention of stroke in patients with diabetes mellitus on previous studies.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup> On the other hand, there has been a report of the beneficial primary prevention effect for stroke in women.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> Previous studies of the primary prevention effect for ischemic stroke showed conflicting results, and the effects might differ according to subjects&#8217; characteristics such as sex and comorbidities and various study design. It has also been suggested that there might be an ethnic difference in the effect of antiplatelet agents, considering habitual status, including eating, and higher intracerebral bleeding risk in Asian populations. Recently conducted studies in Japan showed no beneficial effect of aspirin for the primary prevention of stroke and death in elderly patients with atherosclerotic risk factors.<sup>[<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R24" ref-type="bibr">24</xref>]</sup></p><p>Our study has several limitations. We used NHIS cohort data with a retrospective study design. Although we matched 2 groups regarding the medical status and socioeconomic factors, there might be more confounding factors. For example, we do not divide stroke type in our analysis, and there might be a difference in the primary prevention effect according to stroke subtype.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> In addition, based on our results, although the aspirin group showed an increased risk for mortality, initial stroke severity could be higher compared with the control group considering the mortality rate.</p><p>In conclusion, prior aspirin use was no benefit for neurologic disability and short/long-term mortality after cardiovascular events. In 90-day mortality after cardiovascular events, the old age is a critical factor. So far, no benefit has been demonstrated for aspirin over placebo in the elderly over 70 years of age, and aspirin increased the risk of bleeding, according to recent randomized clinical trials.<sup>[<xref rid="R15" ref-type="bibr">15</xref>&#8211;<xref rid="R17" ref-type="bibr">17</xref>]</sup> Since bleeding is much fatal in the elderly, aspirin prescription for primary prevention should be more careful in the elderly.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Jong Hun Kim, Seo Yeon Yoon, Hyoung Seop Kim.</p><p><bold>Data curation:</bold> Jong Hun Kim, Hyun Sun Lim, Min Jin Kang.</p><p><bold>Formal analysis:</bold> Jong Hun Kim, Dougho Park, Hyun Sun Lim, Min Jin Kang, Jun Hong Lee, Seo Yeon Yoon, Hyoung Seop Kim.</p><p><bold>Funding acquisition:</bold> Jong Hun Kim.</p><p><bold>Investigation:</bold> Jong Hun Kim.</p><p><bold>Methodology:</bold> Jong Hun Kim.</p><p><bold>Project administration:</bold> Jong Hun Kim.</p><p><bold>Resources:</bold> Jong Hun Kim.</p><p><bold>Software:</bold> Jong Hun Kim.</p><p><bold>Supervision:</bold> Jong Hun Kim, Seo Yeon Yoon, Hyoung Seop Kim.</p><p><bold>Validation:</bold> Jong Hun Kim.</p><p><bold>Visualization:</bold> Jong Hun Kim.</p><p><bold>Writing &#8211; original draft:</bold> Jong Hun Kim, Seo Yeon Yoon.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Jong Hun Kim, Dougho Park, Hyun Sun Lim, Min Jin Kang, Jun Hong Lee, Seo Yeon Yoon, Hyoung Seop Kim.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" id="s1" content-type="document" xlink:href="medi-102-e34109-s001.pdf" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" id="s2" content-type="document" xlink:href="medi-102-e34109-s002.pdf" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>HR</term><def><p>hazaad ratio</p></def></def-item><def-item><term>MI</term><def><p>myocardial infarction</p></def></def-item><def-item><term>NHIS</term><def><p>National Health Insurance Service</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This study was supported by National Health Insurance Ilsan Hospital research fund.</p></fn><fn fn-type="other"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The data that support the findings of this study are available from a third party, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.</p></fn><fn fn-type="other"><p>Supplemental Digital Content is available for this article.</p></fn><fn fn-type="other"><p>How to cite this article: Kim JH, Park D, Lim HS, Kang MJ, Lee JH, Yoon SY, Kim HS. Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study. Medicine 2023;102:25(e34109).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baigent</surname><given-names>C</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>L</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R</given-names></name><etal/></person-group>.; <collab>Antithrombotic Trialists' (ATT) Collaboration</collab>. <article-title>Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.</article-title><source>Lancet</source>. <year>2009</year>;<volume>373</volume>:<fpage>1849</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">19482214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(09)60503-1</pub-id><pub-id pub-id-type="pmcid">PMC2715005</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>SC</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Bonow</surname><given-names>RO</given-names></name><etal/></person-group>. <article-title>AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the world heart federation and the preventive cardiovascular nurses association.</article-title><source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>58</volume>:<fpage>2432</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">22055990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2011.10.824</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kernan</surname><given-names>WN</given-names></name><name name-style="western"><surname>Ovbiagele</surname><given-names>B</given-names></name><name name-style="western"><surname>Black</surname><given-names>HR</given-names></name><etal/></person-group>.; <collab>American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease</collab>. <article-title>Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.</article-title><source>Stroke</source>. <year>2014</year>;<volume>45</volume>:<fpage>2160</fpage>&#8211;<lpage>236</lpage>.<pub-id pub-id-type="pmid">24788967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STR.0000000000000024</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piepoli</surname><given-names>MF</given-names></name><name name-style="western"><surname>Hoes</surname><given-names>AW</given-names></name><name name-style="western"><surname>Agewall</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR).</article-title><source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>2315</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">27222591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehw106</pub-id><pub-id pub-id-type="pmcid">PMC4986030</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchiyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>N</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>K</given-names></name><etal/></person-group>.; <collab>JPPP Study Group</collab>. <article-title>Aspirin for stroke prevention in elderly patients with vascular risk factors: Japanese primary prevention project.</article-title><source>Stroke</source>. <year>2016</year>;<volume>47</volume>:<fpage>1605</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">27165949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.115.012461</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seshasai</surname><given-names>SR</given-names></name><name name-style="western"><surname>Wijesuriya</surname><given-names>S</given-names></name><name name-style="western"><surname>Sivakumaran</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.</article-title><source>Arch Intern Med</source>. <year>2012</year>;<volume>172</volume>:<fpage>209</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">22231610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinternmed.2011.628</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelaziz</surname><given-names>HK</given-names></name><name name-style="western"><surname>Saad</surname><given-names>M</given-names></name><name name-style="western"><surname>Pothineni</surname><given-names>NVK</given-names></name><etal/></person-group>. <article-title>Aspirin for primary prevention of cardiovascular events.</article-title><source>J Am Coll Cardiol</source>. <year>2019</year>;<volume>73</volume>:<fpage>2915</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">31196447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2019.03.501</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pignone</surname><given-names>M</given-names></name><name name-style="western"><surname>Alberts</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Colwell</surname><given-names>JA</given-names></name><etal/></person-group>.; <collab>American Diabetes Association</collab>. <article-title>Aspirin for primary prevention of cardiovascular events in people with diabetes.</article-title><source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>2878</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">20579547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2010.04.003</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>T</given-names></name><name name-style="western"><surname>Miller</surname><given-names>T</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S</given-names></name></person-group>. <article-title>Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. preventive services task force.</article-title><source>Ann Intern Med</source>. <year>2009</year>;<volume>150</volume>:<fpage>405</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">19293073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-150-6-200903170-00009</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lala</surname><given-names>A</given-names></name><name name-style="western"><surname>Krantz</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.</article-title><source>Am Heart J</source>. <year>2011</year>;<volume>162</volume>:<fpage>115</fpage>&#8211;<lpage>24.e2</lpage>.<pub-id pub-id-type="pmid">21742097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2011.04.006</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>CS</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>J</given-names></name><name name-style="western"><surname>Metcalf</surname><given-names>AK</given-names></name><etal/></person-group>. <article-title>Prior antiplatelet or anticoagulant therapy and mortality in stroke.</article-title><source>Heart</source>. <year>2012</year>;<volume>98</volume>:<fpage>712</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22327570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/heartjnl-2011-301076</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowlatshahi</surname><given-names>D</given-names></name><name name-style="western"><surname>Hakim</surname><given-names>A</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J</given-names></name><etal/></person-group>.; <collab>Investigators of the Registry of the Canadian Stroke Network</collab>. <article-title>Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the registry of the Canadian stroke network.</article-title><source>Int J Stroke</source><year>2009</year>;<volume>4</volume>:<fpage>328</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">19765119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1747-4949.2009.00331.x</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivenius</surname><given-names>J</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>L</given-names></name><name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name><etal/></person-group>. <article-title>Antiplatelet treatment does not reduce the severity of subsequent stroke. European Stroke prevention study 2 working group.</article-title><source>Neurology</source>. <year>1999</year>;<volume>53</volume>:<fpage>825</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10489049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.53.4.825</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryu</surname><given-names>WS</given-names></name><name name-style="western"><surname>Schellingerhout</surname><given-names>D</given-names></name><name name-style="western"><surname>Hong</surname><given-names>KS</given-names></name><etal/></person-group>. <article-title>Relation of pre-stroke aspirin use with cerebral infarct volume and functional outcomes.</article-title><source>Ann Neurol</source>. <year>2021</year>;<volume>90</volume>:<fpage>763</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">34536234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26219</pub-id><pub-id pub-id-type="pmcid">PMC9292882</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeil</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>MR</given-names></name><name name-style="western"><surname>Woods</surname><given-names>RL</given-names></name><etal/></person-group>.; <collab>ASPREE Investigator Group</collab>. <article-title>Effect of aspirin on all-cause mortality in the healthy elderly.</article-title><source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>1519</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">30221595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1803955</pub-id><pub-id pub-id-type="pmcid">PMC6433466</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeil</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Woods</surname><given-names>RL</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>MR</given-names></name><etal/></person-group>.; <collab>ASPREE Investigator Group</collab>. <article-title>Effect of aspirin on disability-free survival in the healthy elderly.</article-title><source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>1499</fpage>&#8211;<lpage>508</lpage>.<pub-id pub-id-type="pmid">30221596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1800722</pub-id><pub-id pub-id-type="pmcid">PMC6426126</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeil</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>R</given-names></name><name name-style="western"><surname>Woods</surname><given-names>RL</given-names></name><etal/></person-group>.; <collab>ASPREE Investigator Group</collab>. <article-title>Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.</article-title><source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>1509</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">30221597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1805819</pub-id><pub-id pub-id-type="pmcid">PMC6289056</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowman</surname><given-names>L</given-names></name><name name-style="western"><surname>Mafham</surname><given-names>M</given-names></name><name name-style="western"><surname>Wallendszus</surname><given-names>K</given-names></name><etal/></person-group><collab>ASCEND Study Collaborative Group</collab>. <article-title>Effects of aspirin for primary prevention in persons with diabetes mellitus.</article-title><source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>1529</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">30146931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1804988</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaziano</surname><given-names>JM</given-names></name><name name-style="western"><surname>Brotons</surname><given-names>C</given-names></name><name name-style="western"><surname>Coppolecchia</surname><given-names>R</given-names></name><etal/></person-group>.; <collab>ARRIVE Executive Committee</collab>. <article-title>Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.</article-title><source>Lancet</source>. <year>2018</year>;<volume>392</volume>:<fpage>1036</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">30158069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31924-X</pub-id><pub-id pub-id-type="pmcid">PMC7255888</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levesque</surname><given-names>LE</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kezouh</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.</article-title><source>BMJ</source><year>2010</year>;<volume>340</volume>:<fpage>b5087</fpage>.<pub-id pub-id-type="pmid">20228141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.b5087</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S</given-names></name><name name-style="western"><surname>Vanclay</surname><given-names>F</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>B</given-names></name></person-group>. <article-title>Improving the sensitivity of the barthel index for stroke rehabilitation.</article-title><source>J Clin Epidemiol</source>. <year>1989</year>;<volume>42</volume>:<fpage>703</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">2760661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0895-4356(89)90065-6</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>T</given-names></name><etal/></person-group>.; <collab>Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators</collab>. <article-title>Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.</article-title><source>JAMA</source>. <year>2008</year>;<volume>300</volume>:<fpage>2134</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">18997198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2008.623</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Choi</surname><given-names>NK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study.</article-title><source>Diabetol Metab Syndr</source><year>2015</year>;<volume>7</volume>:<fpage>8</fpage>.<pub-id pub-id-type="pmid">25733983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13098-015-0002-y</pub-id><pub-id pub-id-type="pmcid">PMC4346109</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikeda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>K</given-names></name><name name-style="western"><surname>Teramoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.</article-title><source>JAMA</source>. <year>2014</year>;<volume>312</volume>:<fpage>2510</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">25401325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2014.15690</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Ko</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Differential effect of previous antiplatelet use on stroke severity according to stroke mechanism.</article-title><source>Stroke</source>. <year>2010</year>;<volume>41</volume>:<fpage>1200</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">20431078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.110.580225</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>